MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
39.65
-6.06
-13.26%
After Hours: 39.65 0 0.00% 19:30 11/06 EST
OPEN
41.11
PREV CLOSE
45.71
HIGH
41.67
LOW
37.60
VOLUME
759.19K
TURNOVER
--
52 WEEK HIGH
52.61
52 WEEK LOW
24.95
MARKET CAP
740.66M
P/E (TTM)
2.473
1D
5D
1M
3M
1Y
5Y
1D
Rigel Pharmaceuticals Down Over 11%, on Pace for Largest Percent Decrease Since September 2025 -- Data Talk
Dow Jones · 2d ago
Rigel Pharmaceuticals Price Target Raised to $47.00/Share From $43.00 by Cantor Fitzgerald
Dow Jones · 2d ago
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Dow Jones · 2d ago
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $47
Benzinga · 2d ago
Rigel (RIGL) Q3 2026 Earnings Call Transcript
The Motley Fool · 2d ago
Rigel Pharmaceuticals narrows 2026 revenue view to $290M-$295M from $285M-$295M
TipRanks · 3d ago
Rigel Pharmaceuticals reports Q3 EPS 65c, consensus 96c
TipRanks · 3d ago
Rigel’s R289 Clinical Update and Tavalisse Data Support Buy Rating; Price Target Unchanged at $85
TipRanks · 4d ago
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.